Last reviewed · How we verify
TAB014 Monoclonal Antibody Injection — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
TAB014 Monoclonal Antibody Injection (TAB014 Monoclonal Antibody Injection) — BioDlink Biopharm Co., Ltd.. TAB014 is a monoclonal antibody that targets an unspecified molecular target to treat various conditions.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| TAB014 Monoclonal Antibody Injection TARGET | TAB014 Monoclonal Antibody Injection | BioDlink Biopharm Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- TAB014 Monoclonal Antibody Injection CI watch — RSS
- TAB014 Monoclonal Antibody Injection CI watch — Atom
- TAB014 Monoclonal Antibody Injection CI watch — JSON
- TAB014 Monoclonal Antibody Injection alone — RSS
Cite this brief
Drug Landscape (2026). TAB014 Monoclonal Antibody Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/tab014-monoclonal-antibody-injection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab